Omeros Corporation (OMER)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).
The investigation concerns whether Omeros and certain of its officers and/or directors have violated federal securities laws.
On May 20, 2021, Omeros issued a press release “report[ing] that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).” Omeros advised investors that “[t]he new Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021.” On this news, Omeros’s stock price fell sharply during intraday trading on May 20, 2021.
If you are aware of any facts relating to this investigation, or purchased Omeros shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.